Saudi Arabia has shut down half of its oil production after drones attacked the world's largest oil processing facility in the kingdom.Marketsread more
Yemen's Houthi rebels have claimed responsibility for the attacks, which created a huge fire at a processor essential to global energy supplies.Politicsread more
Oil prices are expected to jump as much as $10 per barrel after a coordinated drone strike hit Saudi Arabia's largest oil field, forcing the kingdom to cut its oil output in...Marketsread more
Trusii's hydrogen water machines were supposed to help users with their health problems, but customers claim the company is involved in a giant scam.Technologyread more
The decoupling of the world's two weightiest economies seems as inescapable as its extent and global impact remains incalculable.Politicsread more
The trucking industry is worth hundreds of billions of dollars per year. Uber is going after this market with Uber Freight, an online platform that matches truckers with...Technologyread more
BlackBerry has reinvented itself to become a leader in securing mobile communications and in embedded communications. Next year it plans to roll out new products. CEO John...Evolveread more
Trailers have become a cult phenomenon. Even short teasers that reveal little about the plot of the upcoming film are headline-worthy. Blogs and forums have become devoted...Entertainmentread more
Thanks to the performance of Beyond Meat, investors who focus on venture-backed tech IPOs have done well this year despite some notable disappointments.Technologyread more
Software company Intuit, maker of tax helper TurboTax, is in its eleventh year of stock gains and up 36% this year.Investingread more
CNBC did a deep dive through the most recent Wall Street research to find stocks with upside potential.Marketsread more
Scientists aren't far away from creating blood tests that can be used to detect the earliest stages of cancer, Guardant Health co-founder and CEO Helmy Eltoukhy said Monday.
The Silicon Valley oncology company, backed by SoftBank, is working with U.K.-based AstraZeneca to develop blood tests to help identify cancer patients likely to respond well to treatment with AstraZeneca's oncology therapies.
Bits of cancer DNA can be found in a patient's blood and give doctors clues about which treatments are most likely to work. So-called "liquid biopsy" tests, which can detect this tiny genetic material, are already nearly a standard of care for people with stage 3 or 4 cancer, a cancer that is far along in its growth, Eltoukhy said.
"We're not that far away from seeing the promise becoming a reality of a blood test for early detection," Eltoukhy told CNBC's Meg Tirrell at the 2019 American Society of Clinical Oncology meeting in Chicago.
Doctors have the ability to use tissue biopsies, tiny pieces of tumors removed surgically from patients, to determine which genes are driving cancer growth. However, tissue biopsies can sometimes be difficult to obtain, especially in patients with lung cancer.
Late last year, Eltoukhy said Guardant's product has been used in 50 different types of cancers, but lung cancer is about 45% of the volume because the traditional tissue biopsy is the most difficult and has the highest failure rate.
Guardant expects liquid biopsies to help patients where tissue biopsies cannot. A number of other companies are also working to bring blood-based cancer tests to the market, including Exact Sciences, California-based Grail and Verily-backed Freenome.
Shares of Guardant Health closed more than 1% higher Monday to $78.17 a share. The stock is up more than 142% since it began trading on the Nasdaq in October 2018.